A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

Who May Qualify: - Is at least 18 years when signing the ICF - Has been diagnosed with gMG of MGFA class II, III, or IV - Is seropositive for AChR-Ab - Is treatment-naive for gMG or has been administered AChEI for the treatment of gMG - Had onset of generalized MG signs and/or symptoms within 12 months before screening; candidates who also had onset of ocular MG signs and/or symptoms within 24 months before screening may be enrolled in the study - Has an MG-ADL score ≥5 Who Should NOT Join This Trial: - gMG diagnosis of MGFA class I or V - Underwent a thymectomy prior to screening, except thymectomy for treatment of nonmalignant thymoma prior to the gMG diagnosis - Prior or current use of any of any systemic corticosteroid therapy or nonsteroidal immunosuppressive therapy for the treatment of gMG Always talk to your doctor about whether this trial is right for you.